In a phase 2, single-arm, single-center clinical trial, 22 patients with R/R MM received the combined infusion of the humanized anti-BCMA cells and the murine anti-CD38 CAR-T cells, and 91% of patients had clinical response and 55% of them achieved CR (25). The gene discussed is CD38; the disease is Miyoshi myopathy.